1 / 1

Drug Therapy of Oncological Diseases in Europe

Drug Therapy of Oncological Diseases in Europe. In Europe oncology spending reached $22 billion and oncology growth is at an all time low point . Nearly one third of the global spending on onco -logical drug therapy refers to Europe.

bonner
Download Presentation

Drug Therapy of Oncological Diseases in Europe

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Drug Therapy of Oncological Diseases in Europe In Europe oncology spending reached $22 billion and oncology growth is at an all time low point Nearly one third of the global spending on onco-logical drug therapy refers to Europe. Oncology sales increased within the last ten years, due to innovative thera-pies, including new indica-tions. However oncology growth in Europe 2012 declines continuously. In 2012 it is the lowest within the last ten years, nearly on the same level as pharma overall growth. All periods are Moving Annual Total through June of each year. Source: IMS Health, MIDAS®, MAT Jun 2012 In the oncology pipeline, targeted therapies dominate all major indications Oncology maintains its leading pipeline positionas an area of growth and high potential. Regarding leading classes by number of R&D products (phase II to registered, state: March 2012, source: IMS Health, R&D Focus) oncologicals (437) beat other indi-cation areas (i.e. immunology, rank 2:172, vaccines, rank 3: 107) by far. In the onco-logy pipeline, targeted therapies dominate all major indications. NUMBER OF PRODUCTS* Indication phases II, III, pre-registration and registered, including line extensions of marketed products. Source: IMS R&D Focus, Jun 2012 INFOGRAFIK 10_2/2012

More Related